228 related articles for article (PubMed ID: 15619171)
1. [Spleen rupture in myocardial infarction after administration of GP IIb-IIIa-antagonists].
Feldmann C; Deutsch HJ
Dtsch Med Wochenschr; 2005 Jan; 130(1-2):29-30. PubMed ID: 15619171
[No Abstract] [Full Text] [Related]
2. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
[TBL] [Abstract][Full Text] [Related]
3. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
4. Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Heestermans AA; Van Werkum JW; Hamm C; Dill T; Gosselink AT; De Boer MJ; Van Houwelingen G; Hoorntje JC; Koopmans PC; Ten Berg JM; Van 't Hof AW
J Thromb Haemost; 2009 Oct; 7(10):1612-8. PubMed ID: 19682233
[TBL] [Abstract][Full Text] [Related]
5. What have We learned from ESPRIT? What will we learn from TARGET?
Ferguson JJ
J Invasive Cardiol; 2000 Jun; 12(6):317-9. PubMed ID: 10859719
[No Abstract] [Full Text] [Related]
6. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators.
Zhao XQ; Théroux P; Snapinn SM; Sax FL
Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI.
Otterstad JE; Brosstad F
Scand Cardiovasc J; 2004 Mar; 38(1):9-15. PubMed ID: 15204241
[No Abstract] [Full Text] [Related]
8. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Ernst NM; Suryapranata H; Miedema K; Slingerland RJ; Ottervanger JP; Hoorntje JC; Gosselink AT; Dambrink JH; de Boer MJ; Zijlstra F; van 't Hof AW
J Am Coll Cardiol; 2004 Sep; 44(6):1187-93. PubMed ID: 15364318
[TBL] [Abstract][Full Text] [Related]
9. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
[TBL] [Abstract][Full Text] [Related]
10. [New antiaggregants and their importance for the practitioner].
Tsakiris DA
Ther Umsch; 2003 Jan; 60(1):24-6. PubMed ID: 12638474
[TBL] [Abstract][Full Text] [Related]
11. [Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients].
Münzel TF; Post F
Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S215-8. PubMed ID: 17109252
[TBL] [Abstract][Full Text] [Related]
12. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
[TBL] [Abstract][Full Text] [Related]
13. The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.
Lavi S; Gruberg L; Kapeliovich M; Hammerman H; Boulos M; Grenadier E; Aronson D; Markiewicz W; Beyar R
J Invasive Cardiol; 2005 Jun; 17(6):296-9. PubMed ID: 16003002
[TBL] [Abstract][Full Text] [Related]
14. Impaired myocardial perfusion score and inflammatory markers in patients undergoing primary angioplasty for acute myocardial infarction.
Exaire JE; Fathi RB; Brener SJ; Karha J; Ellis SG; Bhatt DL
Arch Cardiol Mex; 2006; 76(4):376-82. PubMed ID: 17315613
[TBL] [Abstract][Full Text] [Related]
15. Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease.
Chesebro JH; Badimon JJ
N Engl J Med; 1998 May; 338(21):1539-41. PubMed ID: 9593795
[No Abstract] [Full Text] [Related]
16. Impacts of glycoprotein IIb/IIIa inhibition on QT dispersion after successful percutaneous coronary intervention.
Okmen E; Sanli A; Uyarel H; Dayi S; Tartan Z; Cam N
Angiology; 2006; 57(3):273-81. PubMed ID: 16703187
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Hobbach HP; Schuster P
Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
[TBL] [Abstract][Full Text] [Related]
18. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
Campbell P
N Engl J Med; 2001 Nov; 345(21):1573-4; author reply 1574-5. PubMed ID: 11794228
[No Abstract] [Full Text] [Related]
19. [Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].
Radke PW; Schunkert H
Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S204-7. PubMed ID: 17109249
[No Abstract] [Full Text] [Related]
20. Role of tirofiban in the medical treatment of the intermediate-risk patient with an acute coronary syndrome cannot be denied.
Goldberg L; Mekel J
Am J Cardiol; 2000 Dec; 86(12):1401-2. PubMed ID: 11192745
[No Abstract] [Full Text] [Related]
[Next] [New Search]
